This article was originally published in The Gray Sheet
Firm's branched DNA Quantiplex HIV-1 RNA 3.0 viral load test will be released this summer for research use. The device offers improved sensitivity over the current 2.0 version and quantifies "as little as 50 copies/mL and a broad dynamic range (50 to 500,000 copies/mL) that eliminates the need for reflex testing," Chiron says
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.